leisure time -WSS

leisure time

author：fashion 2025-09-06 03:55:35 - browse：612

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Congress must protect the remaining independent doctors

knowledge

WSS

Doctors on social media are being harassed and cyberbullied

Gene editing the human germline: What are the risks?

Argenx readies a blockbuster opportunity with drug for autoimmune disease

AstraZeneca to buy developer of next

Ebola vaccine can save some who are already sick, per new study

UnitedHealth increases loan offers after Change Healthcare outage

knowledge

leisure time

focus

As demand for Covid shots wanes, Moderna seeks its next success

Gene editing the human germline: What are the risks?

Supreme Court strikes down use of affirmative action

App could help diagnose ear infections more accurately — and at home

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Artificial intelligence use in health care faces greater scrutiny in 2024

Hepatitis C has a cure — but many Americans still lack access to it

Neuroscience’s long legacy of racism

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Intermittent fasting comes with a heart risk? Not so fast

focus

Juul documents reveal insider tactics on political lobbying

SCOTUS questions limit to govt efforts to fight misinformation

UnitedHealth increases loan offers after Change Healthcare outage

Plastic surgeons increase patient psychiatric screenings

Latigo launches with $135 million for Vertex

Asbestos, a deadly carcinogen, banned by EPA

focus

knowledge

knowledge

hotspot